United StatesBiotech & Genomic Medicine▲
Biotech Stocks Hit 52-Week Highs on Earnings and Pipeline Updates
Several biotech stocks reached 52-week highs on August 7, 2026, driven by strong quarterly results and clinical progress. Halozyme Therapeutics surged 20% to $103.30 after reporting second-quarter revenue of $481 million, a 48% year-over-year increase, and estimating full-year 2026 revenues of $1.83 billion to $1.91 billion, representing 31% to 37% growth. Fennec Pharmaceuticals rose over 6% to $11.66 following a 71% jump in first-quarter net sales to $15.1 million from its PEDMARK therapy, with second-quarter results due August 11. Avalyn Pharma climbed over 3% to $34.15 after its April IPO raised about $316 million, while advancing inhaled therapies AP01 and AP02 in Phase 2 trials. Amylyx Pharmaceuticals hit $24.60 as it progresses the Phase 3 LUCIDITY trial for Avexitide and completed enrollment in a Phase 1 ALS study. Chemed Corporation reached $552.72 after revising its full-year revenue growth estimate to 8.25% to 9.25%, with a Medicare cap billing limitation of $7,000, and reporting an 8.8% second-quarter revenue increase to $673 million.
About megatrends
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity ▲Demand
Biotech & Genomic Medicine › Oncology Therapeutics ▲Demand
Biotech & Genomic Medicine › Neuroscience & Neurodegenerative ▲Demand
AMLX · Technology · Positive Progress in Phase 3 LUCIDITY trial for Avexitide and completed enrollment in Phase 1 ALS study.
CHE · Capital · Positive Revised full-year revenue growth estimate to 8.25%-9.25% and reported 8.8% Q2 revenue increase.
FENC · Demand · Positive 71% jump in Q1 net sales to $15.1 million from PEDMARK therapy.
HALO · Capital · Positive Q2 revenue of $481 million, up 48% YoY, and raised full-year revenue guidance.
AVLN · Capital · Positive April IPO raised about $316 million, providing funding for pipeline.